GlycoMimetics Inc.

AI Score

XX

Unlock

0.25
0.01 (4.73%)
At close: Apr 24, 2025, 3:59 PM
0.26
3.65%
Pre-market: Apr 25, 2025, 05:08 AM EDT

Company Description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States.

It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.

In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors.

It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein.

The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687.

GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GlycoMimetics Inc.
GlycoMimetics Inc. logo
Country United States
IPO Date Jan 10, 2014
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Stephanie R. Irish CPA

Contact Details

Address:
9708 Medical Center Drive
Rockville, Maryland
United States
Website https://www.glycomimetics.com

Stock Details

Ticker Symbol GLYC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001253689
CUSIP Number 38000Q102
ISIN Number US38000Q1022
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Bruce Johnson Senior Vice President & Chief Commercial Officer
Chinmaya Rath Senior Vice President & Chief Business Officer
Christian B. Dinneen-Long General Counsel & Company Secretary
Shantha Tyavanagimatt Ph.D. Senior Vice President of Technical Operations
Stephanie R. Irish CPA Vice President of Accounting

Latest SEC Filings

Date Type Title
Apr 04, 2025 S-4/A [Amend] Filing
Apr 03, 2025 425 Filing
Apr 03, 2025 425 Filing
Feb 28, 2025 425 Filing
Feb 27, 2025 425 Filing
Feb 25, 2025 425 Filing
Feb 25, 2025 8-K Current Report
Feb 18, 2025 S-4 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 425 Filing